Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Acute tamoxifen-induced depression and its prevention with venlafaxine.

Bourque F, Karama S, Looper K, Cohen V.

Psychosomatics. 2009 Mar-Apr;50(2):162-5. doi: 10.1176/appi.psy.50.2.162.

PMID:
19377026
2.

Quetiapine for tamoxifen-induced insomnia in women with breast cancer.

Pasquini M, Speca A, Biondi M.

Psychosomatics. 2009 Mar-Apr;50(2):159-61. doi: 10.1176/appi.psy.50.2.159.

PMID:
19377025
3.

Tamoxifen in breast cancer: symptom reporting.

Arnold BJ, Cumming CE, Lees AW, Handman MD, Cumming DC, Urion C.

Breast J. 2001 Mar-Apr;7(2):97-100.

PMID:
11328315
4.

Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.

Yang G, Nowsheen S, Aziz K, Georgakilas AG.

Pharmacol Ther. 2013 Sep;139(3):392-404. doi: 10.1016/j.pharmthera.2013.05.005. Epub 2013 May 24. Review.

PMID:
23711794
5.

Tamoxifen in postmenopausal women a safety perspective.

Robinson E, Kimmick GG, Muss HB.

Drugs Aging. 1996 May;8(5):329-37. Review.

PMID:
8935395
7.

Selective estrogen-receptor modulators in 2001.

O'Regan RM, Gradishar WJ.

Oncology (Williston Park). 2001 Sep;15(9):1177-85, 1189-90; discussion 1190-4.

8.

Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.

Hoff PM, Valero V, Buzdar AU, Singletary SE, Theriault RL, Booser D, Asmar L, Frye D, McNeese MD, Hortobagyi GN.

Cancer. 2000 May 1;88(9):2054-60.

PMID:
10813717
9.

Clinical review: Effect of endocrine therapies on bone in breast cancer patients.

Santen RJ.

J Clin Endocrinol Metab. 2011 Feb;96(2):308-19. doi: 10.1210/jc.2010-1679. Epub 2010 Dec 8. Review.

PMID:
21147884
10.

[Surveillance of patients treated with tamoxifen].

Sananes S, Khairallah T, Touboul E, Salat-Baroux J, Uzan S.

Presse Med. 1996 Mar 23;25(10):499-502. Review. French.

PMID:
8685111
11.
12.

[The effects of tamoxifen on the female genital tract].

Mourits MJ, van der Zee AG, Willemse PH, Hollema H, de Vries EG.

Ned Tijdschr Geneeskd. 2003 Nov 22;147(47):2315-20. Review. Dutch.

PMID:
14669536
13.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.

J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2.

PMID:
17200148
14.

Gynaecological aspects of tamoxifen treatment in breast cancer patients.

Obwegeser R, Auerbach L, Kubista E.

Cancer Treat Rev. 1997 Sep-Nov;23(5-6):289-304. Review. No abstract available.

PMID:
9465881
15.

Comparison of two-year and five-year tamoxifen use in Japanese post-menopausal women.

Tada K, Yoshimoto M, Nishimura S, Takahashi K, Makita M, Iwase T, Takahashi S, Ito Y, Hatake K, Ueno M, Nakagawa K, Kasumi F.

Eur J Surg Oncol. 2004 Dec;30(10):1077-83.

PMID:
15522554
16.

Tamoxifen and CYP 2D6 inhibitors: caution.

[No authors listed]

Prescrire Int. 2011 Jul-Aug;20(118):182-4.

PMID:
21751753
17.

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO, Sevelda P.

Lancet. 1996 Apr 20;347(9008):1066-71.

PMID:
8602056
18.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C.

N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

19.

Management of hot flashes in women with breast cancer receiving ovarian function suppression.

Leon-Ferre RA, Majithia N, Loprinzi CL.

Cancer Treat Rev. 2017 Jan;52:82-90. doi: 10.1016/j.ctrv.2016.11.012. Epub 2016 Dec 5. Review.

PMID:
27960127
20.

Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.

Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, Grenier J, Kramar A, Girault J, Le Nestour E, Maudelonde T.

J Clin Oncol. 2005 May 1;23(13):2980-7.

PMID:
15860853

Supplemental Content

Support Center